SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BGLC

BioNexus Gene Lab Corp (NASDAQ:BGLC)

MY · Delayed Price · Currency is USD
Industrials · Industrial - Distribution
$0.68+$0.00 (+0.00%)
 
Market cap
$1.64M
Insider Score
Health Score
Listed since
Jan 8, 2021
Market Cap$1.64M-84.6%
Revenue (ttm)$630.67K-93.3%
Net Income-$2.92M-27.2%
EPS-$1.26+0.8%
Shares Out2.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,066
Open$0.68
Previous Close$0.68
Day's Range$0.68 - $0.73
52-Week Range$0.62 - $4.97
Beta2.20
Analystsn/a
Price Targetn/a
Earnings Daten/a
+0.00% (1D)
No price history available.

About BGLC

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.

Address
Menara UOA Bangsar, Kuala Lumpur, WP, 59000, MY
Market Cap
2 million
Employees
19
Industrial Classification
Industrial - Distribution
Financial Health Score
Sound
From BGLC’s reported statements · Q3 2026 (trailing 12 months)
1 Day
+0.00%
5 Days
-17.07%
1 Month
-42.86%
6 Months
-66.34%
1 Year
-84.58%

$BGLC stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BGLC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BGLC's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BGLC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

BGLC Revenue by Segment or Geography

$394.24KTotal
By Business Unit$146.91K37.27%
By Country$146.91K37.27%
Gain on disposal of investments in equity securities$42.38K10.75%
Fair value gain on investments in equity securities$28.26K7.17%
Dividend income$21.75K5.52%
Other income$6.24K1.58%
Gain from foreign exchange$1.79K0.45%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New BGLC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BGLC from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from BGLC’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.